Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Somatropin - Genentech

Drug Profile

Somatropin - Genentech

Alternative Names: Nutrophin; Nutropin; Nutropin Aq; NutropinAq; SMP 140

Latest Information Update: 12 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Dainippon Sumitomo Pharma; Genentech; Ipsen; Roche
  • Class Growth hormones; Hormonal replacements; Obesity therapies
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Short stature; Somatotropin deficiency; Turner's syndrome
  • No development reported Fibromyalgia

Most Recent Events

  • 08 Jan 2019 Genentech and University of Texas Southwestern Medical Center withdraws a phase II/III trial in HIV infection (In children) in USA prior to enrolment (SC) (NCT00256555)
  • 25 Dec 2018 Genentech and University of Texas Southwestern Medical Center withdraw a phase II/III trial in HIV infection in USA prior to enrolment (NCT00286676)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Somatotropin-deficiency in European Union (SC, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top